Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy
Clinical trial NCT02940639 · COMPLETED
Trial details
- NCT number
- NCT02940639
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2016-10-27
- Primary completion
- 2025-06-03
- Enrollment
- 499
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.